Future work should focus on delineating the molecular signaling thresholds at which PLK4-mediated centrosome amplification transitions from a tolerated aberration to a cancer-initiating event and exploring combination therapies targeting PLK4 along with other cell cycle regulators and possibly inflammatory mediators. This evidence concerns the gene PLK4 and cancer.